Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma

Lordick, F; Chao, J; Buxo, E; van Laarhoven, HWM; Lima, CMR; Lorenzen, S; Dayyani, F; Heinemann, V; Greil, R; Stienen, S; Shitara, K

View this publication in the PUBMED database